Current discovery strategies for hepatocellular carcinoma therapeutics

References

• Petrick JL, Braunlin M, Laversanne M, et al. International trends in liver cancer incidence, overall and by histologic subtype, 1978–2007. Int J Cancer. 2016;139(7):1534–1545.
   PubMed Web of Science ®Google Scholar
• Kang KJ, Ahn KS. Anatomical resection of hepatocellular carcinoma: a critical review of the procedure and its benefits on survival. World J Gastroenterol. 2017;23(7):1139–1146.
   PubMed Web of Science ®Google Scholar
• Ringelhan M, Pfister D, O’Connor T, et al. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19:222–232.
   PubMed Web of Science ®Google Scholar
• Galle PR, Forner A, Llovet JM, et al. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236.
   PubMed Web of Science ®Google Scholar
• Sia D, Villanueva A, Friedman SL, et al. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 2017;152(4):745–761.
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–1173.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63.
   PubMed Web of Science ®Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2016;389(10064):56–66.
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389(10088):2492–2502.
   PubMed Web of Science ®Google Scholar
• Chau I, Peck-Radosavljevic M, Borg C, et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: patient-focused outcome results from the randomised phase III REACH study. Ann Oncol. 2017;81:17–25.
   Google Scholar
• Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19(7):940–952.
   PubMed Web of Science ®Google Scholar
• Ho DW-H, Lo RC-L, Chan L-K, et al. Molecular pathogenesis of hepatocellular carcinoma. Liver Cancer. 2016;5(4):290–302.
   PubMed Web of Science ®Google Scholar
• Desai JR, Ochoa S, Prins PA, et al. Systemic therapy for advanced hepatocellular carcinoma: an update. J Gastrointest Oncol. 2017;8(2):243–255.
   PubMed Web of Science ®Google Scholar
• Inarrairaegui M, Melero I, Sangro B. Immunotherapy of hepatocellular carcinoma: facts and hopes. Clin Cancer Res. 2018;24(7):1518–1524.
   PubMed Web of Science ®Google Scholar
• Fujiwara N, Friedman SL, Goossens N, et al. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol. 2018;68(3):526–549.
   PubMed Web of Science ®Google Scholar
• Tang A, Hallouch O, Chernyak V, et al. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom Radiol. 2018;43(1):13–25.
   PubMed Web of Science ®Google Scholar
• Ledda C, Loreto C, Zammit C, et al. Non‑infective occupational risk factors for hepatocellular carcinoma: a review (Review). Mol Med Rep. 2017;15(2):511–533.
   PubMed Web of Science ®Google Scholar
• Atta ESA, Atta HM, Gad AM, et al. Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients. J Hepatocell Carcinoma. 2016;3:19–24.
   PubMed Web of Science ®Google Scholar
• Kaseb AO, Hanbali A, Cotant M, et al. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature. Cancer. 2010;115(21):4895–4906.
   Web of Science ®Google Scholar
• Versmissen J, Colafella KMM, Koolen SLW, et al. Vascular cardio-oncology: vascular endothelial growth factor inhibitors and hypertension. Cardiovasc Res. 2019;115(5):904–914.
   PubMed Web of Science ®Google Scholar
• Frelin C, Ladoux A, D’Angelo G. Vascular endothelial growth factors and angiogenesis. Ann Endocr. 2000;61(1):70–74.
   Google Scholar
• Eric S, Jean PT, Mathieu B, et al. Neuropilin-1 and neuropilin-2 act as coreceptors, potentiating proangiogenic activity. Blood. 2008;111(4):2036–2045.
   Web of Science ®Google Scholar
• Ling W, Huiyan Z, Ping W, et al. Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration. J Biol Chem. 2003;278(49):48848–48860.
   PubMed Web of Science ®Google Scholar
• Simpson D, Keating GM. Sorafenib: in hepatocellular carcinoma. Drugs. 2008;68(2):251–258.
   PubMed Web of Science ®Google Scholar
• Tol J. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2010;363:2573–2573.
   Web of Science ®Google Scholar
• Valérie B, David M, Abderrahmane B, et al. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist. 2012;17(8):1063–1072.
   PubMed Web of Science ®Google Scholar
• Ahmed K, Jeffrey M, Michiko I, et al. Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. Onco Targets Ther. 2016;9:773–780.
   PubMed Web of Science ®Google Scholar
• Wang-Yuan Z, Jiang-Zheng Z, Lu YD, et al. Clinical efficacy of metronomic chemotherapy after cool-tip radiofrequency ablation in the treatment of hepatocellular carcinoma. Int J Hyperthermia. 2016;32(2):193–198.
   PubMed Web of Science ®Google Scholar
• Woo K, Stewart S, Kong G, et al. Identification of a thalidomide derivative that selectively targets tumorigenic liver progenitor cells and comparing its effects with lenalidomide and sorafenib. Eur J Med Chem. 2016;120:275–283.
   PubMed Web of Science ®Google Scholar
• Nicola N, Antonella DL, Caterina B, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366(1):2–16.
   PubMed Web of Science ®Google Scholar
• Blobel CP. ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol. 2005;6(1):32–43.
   PubMed Web of Science ®Google Scholar
• Jorissen RN, Walker F, Pouliot N, et al. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 2003;284(1):31–53.
   PubMed Web of Science ®Google Scholar
• Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell. 2002;110(6):669–672.
   PubMed Web of Science ®Google Scholar
• Komposch K, Sibilia M. EGFR signaling in liver diseases. Int J Mol Sci. 2015;17(1):30–61.
   Web of Science ®Google Scholar
• Daveau M, Scotte M, Ros G, et al. Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol Carcinog. 2003;36(3):130–141.
   PubMed Web of Science ®Google Scholar
• Ito Y, Takeda T, Sakon M, et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer. 2001;84(10):1377–1383.
   PubMed Web of Science ®Google Scholar
• Noboru M, Hiroaki S, Masayuki O, et al. Angiopoietins and Tie-2 expression in angiogenesis and proliferation of human hepatocellular carcinoma. Hepatology. 2010;37(5):1105–1113.
   Google Scholar
• Dipok Kumar D, Takashi O, Akira Y, et al. Serum endostatin predicts tumor vascularity in hepatocellular carcinoma. Cancer. 2010;95(10):2188–2195.
   Google Scholar
• Sachiko O, Hirohisa Y, Seiya M, et al. Expression of matrix metalloproteinases (MMPs) in cultured hepatocellular carcinoma (HCC) cells and surgically resected HCC tissues. Oncol Rep. 2005;13(6):1043–1048.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Keith S, Blaszkowsky LS, et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer. 2010;110(3):581–589.
   Web of Science ®Google Scholar
• Tanaka S, Arii S. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2010;48(4):1312–1327.
   Web of Science ®Google Scholar
• Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24(12):1898–1903.
   PubMed Web of Science ®Google Scholar
• Amani A, Laetitia F, Olivier R, et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer. 2010;112(12):2733–2739.
   Web of Science ®Google Scholar
• Alexander H, Michael HP, Sutter AP, et al. Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics. J Hepatol. 2005;43(4):661–669.
   PubMed Web of Science ®Google Scholar
• Michael HP, Sutter AP, Alexander H, et al. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J Hepatol. 2004;41(6):1008–1016.
   PubMed Web of Science ®Google Scholar
• Philip PA, Mahoney MR, Cristine A, et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol. 2005;23(27):6657–6663.
   PubMed Web of Science ®Google Scholar
• Gajiwala KS, Feng J, Ferre R, et al. Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition. Structure. 2013;21(2):209–219.
   PubMed Web of Science ®Google Scholar
• Jin H, Park YL, Lemmon MA, et al. Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain. Biochem J. 2012;448(Pt 3):417–423.
   PubMed Web of Science ®Google Scholar
• Song Z, Huang S, Yu H, et al. Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC). Eur J Med Chem. 2017;133:329–339.
   PubMed Web of Science ®Google Scholar
• Hossam M, Lasheen DS, Ismail NSM, et al. Discovery of anilino-furo[2,3- d]pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity. Eur J Med Chem. 2017;144:330–348.
   PubMed Web of Science ®Google Scholar
• Yang S, Liu G. Targeting the Ras/Raf/MEK/ERK pathway in hepatocellular carcinoma. Oncol Lett. 2017;13(3):1041–1047.
   PubMed Web of Science ®Google Scholar
• Ward AF, Braun BS, Shannon KM. Targeting oncogenic Ras signaling in hematologic malignancies. Blood. 2012;120(17):3397–3406.
   PubMed Web of Science ®Google Scholar
• Young-A H, Syed YY. Regorafenib: a review in hepatocellular carcinoma. Drugs. 2018;78(9):951–958.
   PubMed Web of Science ®Google Scholar
• Ito Y, Sasaki Y, Horimoto M, et al. Activation of mitogen-activated protein kinases extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology. 1998;27(4):951–958.
   PubMed Web of Science ®Google Scholar
• Zuo Q, Huang H, Shi M, et al. Multivariate analysis of several molecular markers and clinicopathological features in postoperative prognosis of hepatocellular carcinoma. Anat Rec. 2012;295(3):423–431.
   Google Scholar
• Hoffmann K, Lin S, Xiao Z, et al. Correlation of gene expression of ATP-binding cassette protein and tyrosine kinase signalling pathway in patients with hepatocellular carcinoma. Anticancer Res. 2011;31(11):3883–3890.
   PubMed Web of Science ®Google Scholar
• Charette N, Saeger CD, Lannoy V, et al. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition. Mol Cancer. 2010;9(1):256–260.
   PubMed Web of Science ®Google Scholar
• Roy B, Ran E, Shira Y, et al. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid). Cancer Res. 2007;67(7):3320–3328.
   PubMed Web of Science ®Google Scholar
• Koeberle D, Dufour JF, Demeter G, et al. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Ann Oncol Off J Eur Soc Med Oncol. 2016;27(5):856–861.
   PubMed Web of Science ®Google Scholar
• Yong-Song G, Qing H. Sorafenib: activity and clinical application in patients with hepatocellular carcinoma. Expert Opin Pharmacother. 2011;12(2):303–313.
   PubMed Web of Science ®Google Scholar
• Li L, Yichen C, Charles C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006;66(24):11851–11858.
   PubMed Web of Science ®Google Scholar
• Jiao Y, Xin BT, Zhang Y, et al. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents. Eur J Med Chem. 2015;90:170–183.
   PubMed Web of Science ®Google Scholar
• Sith S, Hjelmeland AB, Keir ST, et al. AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma. Cancer Res. 2006;66(17):8722–8730.
   PubMed Web of Science ®Google Scholar
• Cotrim CZ, Amado FL, Helguero LA. Estrogenic effect of the MEK1 inhibitor PD98059 on endogenous estrogen receptor alpha and beta. J Steroid Biochem Mol Biol. 2011;124(1):25–30.
   PubMed Web of Science ®Google Scholar
• Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 2009;283(2):125–134.
   PubMed Web of Science ®Google Scholar
• Barrett SD, Bridges AJ, Dudley DT, et al. The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. Bioorg Med Chem Lett. 2008;18(24):6501–6504.
   PubMed Web of Science ®Google Scholar
• LoRusso PM, Krishnamurthi SS, Rinehart JJ, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res. 2010;16(6):1924–1937.
   PubMed Web of Science ®Google Scholar
• O’Neil BH, Goff LW, Kauh JSW, et al. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(17):2350–2356.
   PubMed Web of Science ®Google Scholar
• Sousa N, Sousa O, Santos LL, et al. Lapatinib-capecitabine versus capecitabine alone as radiosensitizers in RAS wild-type resectable rectal cancer, an adaptive randomized phase II trial (LaRRC trial): study protocol for a randomized controlled trial. Trials. 2016;17(1):459–472.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Hernandez-Gea V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res. 2014;20(8):2072–2079.
   PubMed Web of Science ®Google Scholar
• Ma F, Liu P, Lei M, et al. Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3). Eur J Med Chem. 2016;127:72–86.
   PubMed Web of Science ®Google Scholar
• Beretta GL, Cassinelli G, Pennati M, et al. Overcoming ABC transporter-mediated multidrug resistance: the dual role of tyrosine kinase inhibitors as multitargeting agents. Eur J Med Chem. 2017;142:271–289.
   PubMed Web of Science ®Google Scholar
• Kern MA, Schirmacher P, Breinig M. Cyclooxygenase-2 (COX-2) - a therapeutic target in liver cancer? Curr Pharm Des. 2007;13(32):3305–3315.
   PubMed Web of Science ®Google Scholar
• Takami Y, Tateishi M, Ryu T, et al. A randomised controlled trial of meloxicam, a COX-2 inhibitor, to prevent hepatocellular carcinoma recurrence after initial curative treatment. Hepatol Int. 2016;10(5):799–806.
   PubMed Web of Science ®Google Scholar
• Marco B, Peter S, Michael André K. Cyclooxygenase-2 (COX-2)–a therapeutic target in liver cancer? Curr Pharm Des. 2007;13(32):3305–3315.
   PubMed Web of Science ®Google Scholar
• Wang JL, Limburg D, Graneto MJ, et al. The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: the second clinical candidate having a shorter and favorable human half-life. Bioorg Med Chem Lett. 2010;20(23):7159–7163.
   PubMed Web of Science ®Google Scholar
• Tai D, Tsai S, Chang YH, et al. Constitutive activation of nuclear factor kappaB in hepatocellular carcinoma. Cancer. 2015;89(11):2274–2281.
   Web of Science ®Google Scholar
• Chiao PJ, Ren N, Jiangong N, et al. Role of Rel/NF-kappaB transcription factors in apoptosis of human hepatocellular carcinoma cells. Cancer. 2002;95(8):1696–1705.
   PubMed Web of Science ®Google Scholar
• Jr ASB. THE NF-κB AND IκB PROTEINS: new discoveries and insights. Annu Rev Immunol. 1996;14(1):649–683.
   PubMed Web of Science ®Google Scholar
• Verma IM, Stevenson JK, Schwarz EM, et al. Rel/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev. 1995;9(22):2723–2735.
   PubMed Web of Science ®Google Scholar
• Chiao PJ, Ren N, Niu J, et al. Role of Rel/NF-?B transcription factors in apoptosis of human hepatocellular carcinoma cells. Cancer. 2010;95(8):1696–1705.
   Web of Science ®Google Scholar
• Chen D, Frezza M, Schmitt S, et al. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Tar. 2011;11(3):239–253.
   PubMed Web of Science ®Google Scholar
• Kim GP, Mahoney MR, Daniel S, et al. An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma. Invest New Drug. 2012;30(1):387–394.
   PubMed Web of Science ®Google Scholar
• Ashley JD, Stefanick JF, Schroeder VA, et al. Liposomal bortezomib nanoparticles via boronic ester prodrug formulation for improved therapeutic efficacy in vivo. J Med Chem. 2015;57(12):5282–5292.
   Web of Science ®Google Scholar
• Han LQ, Yuan X, Wu XY, et al. Urea-containing peptide boronic acids as potent proteasome inhibitors. Eur J Med Chem. 2017;125(Complete):925–939.
   PubMed Web of Science ®Google Scholar
• Jiankang Z, Luqing S, Jincheng W, et al. Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors. Med Chem. 2014;10(1):180–191.
   Web of Science ®Google Scholar
• Micale N, Ettari R, Lavecchia A, et al. Development of peptidomimetic boronates as proteasome inhibitors. Eur J Med Chem. 2013;64(6):23–34.
   PubMed Web of Science ®Google Scholar
• Thorpe LM, Haluk Y, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15(1):7–24.
   PubMed Web of Science ®Google Scholar
• Haijuan Y, Rudge DG, Koos JD, et al. mTOR kinase structure, mechanism and regulation. Nature. 2013;497(7448):217–223.
   PubMed Web of Science ®Google Scholar
• Qian Z, Lui VWY, Winnie Y. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncol. 2011;7(10):1149–1167.
   PubMed Web of Science ®Google Scholar
• Wolfgang S, Thorsten F, Katharina S, et al. Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation. Transplantation. 2007;83(4):425–432.
   PubMed Web of Science ®Google Scholar
• Zhang B, Wang N, Zhang C, et al. Novel multi-substituted benzyl acridone derivatives as survivin inhibitors for hepatocellular carcinoma treatment. Eur J Med Chem. 2017;129:337–348.
   PubMed Web of Science ®Google Scholar
• Wang N, Chen S, Zhang B, et al. 8u, a pro-apoptosis/cell cycle arrest compound, suppresses invasion and metastasis through HSP90α downregulating and PI3K/Akt inactivation in hepatocellular carcinoma cells. Sci Rep. 2018;8(1):309–321.
   PubMed Web of Science ®Google Scholar
• Li W, Gao C, Zhao L, et al. Phthalimide conjugations for the degradation of oncogenic PI3K. Eur J Med Chem. 2018;151:237–247.
   PubMed Web of Science ®Google Scholar
• Korangy F, Höchst B, Manns MP, et al. Immunotherapy of hepatocellular carcinoma. Oncoimmunology. 2014;1(1):48–55.
   Google Scholar
• Qin S, Finn RS, Kudo M, et al. RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Future Oncol. 2019;15(16):1811–1822.
   PubMed Web of Science ®Google Scholar
• Teng Y, Guo R, Sun J, et al. Reactive capillary hemangiomas induced by camrelizumab (SHR-1210), an anti-PD-1 agent. Acta Oncologica. 2019;58(3):388–389.
   PubMed Web of Science ®Google Scholar
• Bang YJ, Goff LW, Wasserstrom H, et al. An open-label, multicenter, phase 1 study of ramucirumab (R) plus durvalumab (D) in patients (pts) with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or hepatocellular carcinoma. Ann Oncol. 2016;27:359–378.
   PubMed Web of Science ®Google Scholar
• Suvà ML, Nicolo R, Bernstein BE. Epigenetic reprogramming in cancer. Science. 2013;339(6127):1567–1570.
   PubMed Web of Science ®Google Scholar
• Esteller M. Epigenetics in cancer. New Engl J Med. 2008;358:1148–1159.
   PubMed Web of Science ®Google Scholar
• Kelly TK, Carvalho DD, De, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol. 2010;28(10):1069–1078.
   PubMed Web of Science ®Google Scholar
• Anestopoulos I, Voulgaridou GP, Georgakilas AG, et al. Epigenetic therapy as a novel approach in hepatocellular carcinoma. Pharmacol Ther. 2015;145:103–119.
   PubMed Web of Science ®Google Scholar
• Illingworth RS, Bird AP. CpG islands – ‘A rough guide’. FEBS Lett. 2009;583(11):1713–1720.
   PubMed Web of Science ®Google Scholar
• Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol. 1987;196(2):261–282.
   PubMed Web of Science ®Google Scholar
• Baylin SB. DNA methylation and gene silencing in cancer. Nature Clin Pract Oncol. 2005;2:S4–11.
   PubMedGoogle Scholar
• Ina R, Bachman KE, Ben Ho P, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature. 2002;416(6880):552–556.
   PubMed Web of Science ®Google Scholar
• Bestor TH. Activation of mammalian DNA methyltransferase by cleavage of a Zn binding regulatory domain. Embo J. 1992;11(7):2611–2617.
   PubMed Web of Science ®Google Scholar
• Yoshimasa S, Yae K, Tohru N, et al. Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas. Int J Cancer. 2003;105(4):527–532.
   PubMed Web of Science ®Google Scholar
• Sceusi EL, Loose DS, Wray CJ. Clinical implications of DNA methylation in hepatocellular carcinoma. Hpb. 2011;13(6):369–376.
   PubMed Web of Science ®Google Scholar
• Delgado-Cruzata L, Brubaker W, Wu HC, et al. Abstract 3754: DNA methylation in hepatocellular carcinoma. Cancer Res. 2011;71(8):3754–3754.
   Google Scholar
• Tischoff I, Tannapfel A. DNA methylation in hepatocellular carcinoma. World J Gastroenterol. 2008;14(11):1741–1748.
   PubMed Web of Science ®Google Scholar
• Hye-Jung P, Eunsil Y, Yhong-Hee S. DNA methyltransferase expression and DNA hypermethylation in human hepatocellular carcinoma. Cancer Lett. 2006;233(2):271–278.
   PubMed Web of Science ®Google Scholar
• Eads CA, Danenberg KD, Kawakami K, et al. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res. 1999;59(10):2302–2306.
   PubMed Web of Science ®Google Scholar
• Pfister SX, Ashworth A. Marked for death: targeting epigenetic changes in cancer. Nat Rev Drug Discov. 2017;16(4):241–263.
   PubMed Web of Science ®Google Scholar
• Biswas S, Rao CM. Epigenetics in cancer: fundamentals and beyond. Pharmacol Ther. 2017;173:118–134.
   PubMed Web of Science ®Google Scholar
• Alexandre E, Ludovic H, Jacques F, et al. Targeting DNA methylation with small molecules: what’s next? J Med Chem. 2015;58(6):2569–2583.
   PubMed Web of Science ®Google Scholar
• Martinet N, Michel BY, Bertrand P, et al. Small molecules DNA methyltransferases inhibitors. Medchemcommun. 2012;3(3):263–273.
   Web of Science ®Google Scholar
• Isakovic L, Saavedra OM, Llewellyn DB, et al. Constrained (l-)-S-adenosyl-l-homocysteine (SAH) analogues as DNA methyltransferase inhibitors. Bioorg Med Chem Lett. 2009;19(10):2742–2746.
   PubMed Web of Science ®Google Scholar
• Agnieszka G, Zenon J, Sylwia F. DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer. Anticancer Res. 2013;33(8):2989–2996.
   PubMed Web of Science ®Google Scholar
• Frank L, Robert B. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst. 2005;97(20):1498–1506.
   PubMedGoogle Scholar
• Sajadian SO, Tripura C, Samani FS, et al. Vitamin C enhances epigenetic modifications induced by 5-azacytidine and cell cycle arrest in the hepatocellular carcinoma cell lines HLE and Huh7. Clin Epigenetics. 2016;8(1):46–58.
   PubMed Web of Science ®Google Scholar
• Witt O, Deubzer HE, Milde T, et al. HDAC family: what are the cancer relevant targets? Cancer Lett. 2009;277(1):8–21.
   PubMed Web of Science ®Google Scholar
• Li Y, Seto E. HDACs and HDAC inhibitors in cancer development and therapy. Cold Spring Harb Perspect Med. 2016;6(10):a026831–026843.
   PubMed Web of Science ®Google Scholar
• West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Investig. 2014;124(1):30–39.
   PubMed Web of Science ®Google Scholar
• New M, Olzscha H, Thangue NBL. HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol. 2012;6(6):637–656.
   PubMed Web of Science ®Google Scholar
• Arrowsmith CH, Bountra C, Fish PV, et al. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov. 2012;11(5):384–400.
   PubMed Web of Science ®Google Scholar
• Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov. 2014;13(9):673–691.
   PubMed Web of Science ®Google Scholar
• Goto K, Annan DA, Morita T, et al. Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study. Sci Rep. 2016;6(1):38407–38440.
   PubMed Web of Science ®Google Scholar
• Yuan-Ling L, Pei-Ming Y, Chia-Tung S, et al. Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma. Autophagy. 2010;6(8):1057–1065.
   PubMed Web of Science ®Google Scholar
• Carlisi D, Lauricella M, D’Anneo A, et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation. Eur J Cancer. 2009;45(13):2425–2438.
   PubMed Web of Science ®Google Scholar
• Bradner JE, West N, Grachan ML, et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010;6(3):238–243.
   PubMed Web of Science ®Google Scholar
• Mann B, Johnson J, Mh Justice R, et al. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12(10):1247–1252.
   PubMed Web of Science ®Google Scholar
• Sun WJ, Huang H, He B, et al. Romidepsin induces G2/M phase arrest via Erk/cdc25C/cdc2/cyclinB pathway and apoptosis induction through JNK/c-Jun/caspase3 pathway in hepatocellular carcinoma cells. Biochem Pharmacol. 2017;127:90–100.
   PubMed Web of Science ®Google Scholar
• Amirikordestani L, Luchenko V, Peer CJ, et al. Phase I trial of a new schedule of romidepsin in patients with advanced cancers. Clin Cancer Res. 2013;19(16):4499–4507.
   PubMed Web of Science ®Google Scholar
• Frye R, Myers M, Axelrod KC, et al. Romidepsin: a new drug for the treatment of cutaneous T-cell lymphoma. Clin J Oncol Nurs. 2012;16(2):195–204.
   PubMed Web of Science ®Google Scholar
• Wang H, Guo Y, Fu M, et al. Antitumor activity of chidamide in hepatocellular carcinoma cell lines. Mol Med Rep. 2012;5(6):1503–1508.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Laubach JP, Sagar L, et al. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. Expert Rev Anticancer Ther. 2015;15(9):1121–1131.
   PubMed Web of Science ®Google Scholar
• Susanne G, Christian M, Tobias K, et al. The pan-deacetylase inhibitor panobinostat affects angiogenesis in hepatocellular carcinoma models via modulation of CTGF expression. Int J Oncol. 2015;47(3):963–970.
   PubMed Web of Science ®Google Scholar
• Xuan S, Jiabei W, Tongsen Z, et al. LBH589 inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/stat3/akt pathway. Mol Cancer. 2013;12(1):114.
   PubMed Web of Science ®Google Scholar
• Liu KY, Wang LT, Hsu SH. Modification of epigenetic histone acetylation in hepatocellular carcinoma. Cancers (Basel). 2018;10(1):8–21.
   Web of Science ®Google Scholar
• Mcgranahan N, Swanton C. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell. 2015;27(1):15–26.
   PubMed Web of Science ®Google Scholar
• Easwaran H, Tsai H-C, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell. 2014;54(5):716–727.
   PubMed Web of Science ®Google Scholar
• Wu Q, Yang Z, Nie Y, et al. Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches. Cancer Lett. 2014;347(2):159–166.
   PubMed Web of Science ®Google Scholar
• Housman G, Byler S, Heerboth S, et al. Drug resistance in cancer: an overview. Cancers (Basel). 2014;6(3):1769–1792.
   PubMed Web of Science ®Google Scholar
• Alakhova DY, Kabanov AV. Pluronics and MDR reversal: an update. Mol Pharm. 2014;11(8):2566–2578.
   PubMed Web of Science ®Google Scholar